Voloridge Investment Management Decreased Esperion Therapeutics Ne (ESPR) Stake; Semgroup Has 1.15 Sentiment

February 23, 2018 - By Michael Collier

Voloridge Investment Management Llc decreased Esperion Therapeutics Inc Ne (ESPR) stake by 9.71% reported in 2017Q3 SEC filing. Voloridge Investment Management Llc sold 9,839 shares as Esperion Therapeutics Inc Ne (ESPR)’s stock rose 33.24%. The Voloridge Investment Management Llc holds 91,480 shares with $4.59M value, down from 101,319 last quarter. Esperion Therapeutics Inc Ne now has $2.06B valuation. The stock decreased 0.08% or $0.06 during the last trading session, reaching $77.88. About 123,133 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 133.75% since February 23, 2017 and is uptrending. It has outperformed by 117.05% the S&P500.

SemGroup Corporation provides gathering, transportation, storage, distribution, marketing, and other midstream services for producers, refiners of petroleum products, and other market participants. The company has market cap of $1.99 billion. The Company’s Crude Transportation segment operates crude oil pipelines and truck transportation businesses. It currently has negative earnings. This segment operates a 460-mile crude oil gathering and transportation pipeline system in Kansas and northern Oklahoma; a 75-mile crude oil gathering pipeline system that transports crude oil from production facilities in the DJ Basin to the pipeline owned by White Cliffs Pipeline, L.L.C.; a 527-mile pipeline that transports crude oil from Platteville, Colorado to Cushing, Oklahoma; and a 215-mile crude oil pipeline in western and north central Oklahoma, as well as crude oil trucking fleet of 225 transport trucks and 235 trailers.

Analysts await SemGroup Corporation (NYSE:SEMG) to report earnings on February, 26 before the open. They expect $0.03 EPS, down 83.33% or $0.15 from last year’s $0.18 per share. SEMG’s profit will be $2.36 million for 210.83 P/E if the $0.03 EPS becomes a reality. After $0.60 actual EPS reported by SemGroup Corporation for the previous quarter, Wall Street now forecasts -95.00% negative EPS growth.

The stock increased 5.42% or $1.3 during the last trading session, reaching $25.3. About 1.15M shares traded or 9.09% up from the average. SemGroup Corporation (SEMG) has risen 7.33% since February 23, 2017 and is uptrending. It has underperformed by 9.37% the S&P500.

Chickasaw Capital Management Llc holds 4.9% of its portfolio in SemGroup Corporation for 7.93 million shares. Eagle Global Advisors Llc owns 3.51 million shares or 3.04% of their US portfolio. Moreover, Yorkville Capital Management Llc has 2.61% invested in the company for 78,568 shares. The Pennsylvania-based Harvest Fund Advisors Llc has invested 2.22% in the stock. Cushing Asset Management Lp, a Texas-based fund reported 2.18 million shares.

Investors sentiment increased to 1.67 in Q3 2017. Its up 0.45, from 1.22 in 2017Q2. It increased, as 11 investors sold ESPR shares while 34 reduced holdings. 30 funds opened positions while 45 raised stakes. 22.73 million shares or 17.55% more from 19.33 million shares in 2017Q2 were reported. Deutsche Bankshares Ag holds 117,987 shares or 0% of its portfolio. Vanguard Inc owns 880,323 shares. 20,500 are owned by Rhumbline Advisers. Fmr Limited Com invested 0.01% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Metropolitan Life Ins New York reported 10,896 shares or 0% of all its holdings. 9,092 were reported by Stifel. Us Savings Bank De stated it has 11,051 shares or 0% of all its holdings. Schwab Charles Mngmt accumulated 91,843 shares or 0% of the stock. Sei Invs holds 1,020 shares or 0% of its portfolio. Laurion Capital Lp owns 0% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 10,800 shares. Invesco accumulated 174,097 shares. Voloridge Invest Mgmt Lc stated it has 0.1% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Discovery Cap Ltd Liability Corporation Ct has 0.94% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Aperio Grp Ltd Llc stated it has 5,398 shares. Maryland-based Proshare Advisors Limited Liability Com has invested 0.01% in Esperion Therapeutics, Inc. (NASDAQ:ESPR).

Analysts await Esperion Therapeutics, Inc. (NASDAQ:ESPR) to report earnings on February, 28. They expect $-1.80 EPS, down 39.53% or $0.51 from last year’s $-1.29 per share. After $-1.86 actual EPS reported by Esperion Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -3.23% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>